Tonlamarsen

About Kardigan

Kardigan is a private, pre-revenue biotech focused on transforming cardiovascular medicine through a pipeline of late-stage, targeted small molecule therapies. The company has three active clinical programs targeting genetic dilated cardiomyopathy, acute severe hypertension, and calcific aortic stenosis, with recent positive Phase 2 data announced for its hypertension candidate. Led by a seasoned team with a successful exit history, including CEO Tassos Gianakakos who previously led MyoKardia to a $13.1B acquisition, Kardigan combines deep cardiovascular expertise with an AI-enhanced platform to pursue functional cures for major heart diseases.

Therapeutic Areas